Literature DB >> 23321280

Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.

Betzaida Cuevas-Córdoba1, Sheila Oyuki Xochihua-González, Aremy Cuellar, Javier Fuentes-Domínguez, Roberto Zenteno-Cuevas.   

Abstract

Numerous studies have linked mutations in the pncA gene with resistance to pyrazinamide (Z) in Mycobacterium tuberculosis. However, variations in these mutations are specific to the country of origin of the isolate. The aim of this study was to characterize changes in pncA gene sequence in isolates of M. tuberculosis with resistance to Z, from patients in Mexico. M. tuberculosis isolates were recovered from individuals suspected of carrying drug resistant tuberculosis and respective susceptibility tests were developed. In isolates with resistance to pyrazinamide the pncA gene and its promoter were analyzed by capillary sequencing. From 127 drug-resistant isolates collected, 42 (33%) were resistant to pyrazinamide. The pncA sequences showed 26 changes in 34 (81%) isolates: 18 SNPs (n=26, 62%), four insertions (n=4, 9.5%) and four deletions (n=4, 9.5%). Absence of modifications was observed in eight (19%) sequences/isolates. The most frequent changes were the mutations L120P (n=7) and K96R (n=4). Twelve changes found are reported for the first time. This is the first description of pncA gene modifications in pyrazinamide resistant isolates originating in Mexico. We conclude that the diversity of changes in pncA indicates the presence of a noteworthy variety of pyrazinamide resistant strains occurring in the area.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug-resistance; Pyrazinamide; Tuberculosis; pncA mutations

Mesh:

Substances:

Year:  2013        PMID: 23321280     DOI: 10.1016/j.meegid.2012.12.013

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  9 in total

1.  Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.

Authors:  Michael G Whitfield; Robin M Warren; Elizabeth M Streicher; Samantha L Sampson; Frik A Sirgel; Paul D van Helden; Alexandra Mercante; Melisa Willby; Kelsey Hughes; Kris Birkness; Glenn Morlock; Annelies van Rie; James E Posey
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

2.  Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Authors:  Peng Xu; Jie Wu; Chongguang Yang; Tao Luo; Xin Shen; Yangyi Zhang; Chijioke A Nsofor; Guofeng Zhu; Brigitte Gicquel; Qian Gao
Journal:  Tuberculosis (Edinb)       Date:  2016-03-03       Impact factor: 3.131

Review 3.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

4.  Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda.

Authors:  Willy Ssengooba; Conor J Meehan; Deus Lukoye; George William Kasule; Kenneth Musisi; Moses L Joloba; Frank G Cobelens; Bouke C de Jong
Journal:  Infect Genet Evol       Date:  2016-02-23       Impact factor: 3.342

5.  A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.

Authors:  S M Ramirez-Busby; T C Rodwell; L Fink; D Catanzaro; R L Jackson; M Pettigrove; A Catanzaro; F Valafar
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

6.  Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico.

Authors:  Carlos Francisco Madrazo-Moya; Irving Cancino-Muñoz; Betzaida Cuevas-Córdoba; Vanessa González-Covarrubias; Martín Barbosa-Amezcua; Xavier Soberón; Raquel Muñiz-Salazar; Armando Martínez-Guarneros; Claudia Bäcker; José Zarrabal-Meza; Clara Sampieri-Ramirez; Antonio Enciso-Moreno; Michael Lauzardo; Iñaki Comas; Roberto Zenteno-Cuevas
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

7.  Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China.

Authors:  Zhimin Cao; Yuanbo Lan; Ling Chen; Min Xiang; Zhiyuan Peng; Jianyong Zhang; Hong Zhang
Journal:  Infect Drug Resist       Date:  2019-09-30       Impact factor: 4.003

Review 8.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

9.  High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.

Authors:  Resty Naluyange; Gerald Mboowa; Kevin Komakech; Derrick Semugenze; David Patrick Kateete; Willy Ssengooba
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.